{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:21Z","timestamp":1786991241803,"version":"build-2736575974"},"reference-count":123,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Radiology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jacr.2023.02.010","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T15:13:58Z","timestamp":1684941238000},"page":"S187-S210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S","title":["ACR Appropriateness Criteria\u00ae Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update"],"prefix":"10.1016","volume":"20","author":[{"given":"Oguz","family":"Akin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungmin","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aytekin","family":"Oto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielia","family":"Gerena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Mankowski","family":"Gettle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir S.","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Pat","family":"Whitworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nikolaidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacr.2023.02.010_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jacr.2023.02.010_bib2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1464-410X.2011.10365.x","article-title":"The economic burden of prostate cancer","volume":"108","author":"Roehrborn","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/PAS.0b013e31817fb3a0","article-title":"Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens","volume":"32","author":"Evans","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jacr.2023.02.010_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00428-006-0254-x","article-title":"Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911)","volume":"449","author":"van der Kwast","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jacr.2023.02.010_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2214\/AJR.06.0401","article-title":"Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology","volume":"188","author":"Graser","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2023.02.010_bib6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacr.2023.02.010_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2012.11324.x","article-title":"An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011","volume":"111","author":"Eifler","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib8","first-page":"898","article-title":"External validation of the updated Partin tables in a cohort of North American men","volume":"180","author":"Karakiewicz","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib9","first-page":"105","article-title":"Validation of the partin nomogram for prostate cancer in a national sample","volume":"183","author":"Yu","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib10","first-page":"1041","article-title":"Added value of multiparametric magnetic resonance imaging to clinical nomograms for predicting adverse pathology in prostate cancer","volume":"200","author":"Rayn","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235779","article-title":"Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy","volume":"15","author":"Sandeman","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jacr.2023.02.010_bib12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/pros.23197","article-title":"External validation of a\u00a0PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy","volume":"76","author":"Greene","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.jacr.2023.02.010_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201384","article-title":"Optimizing patient\u2019s selection for prostate biopsy: a single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer","volume":"13","author":"Punnen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jacr.2023.02.010_bib14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.euo.2018.09.008","article-title":"A\u00a0unified prostate cancer risk prediction model combining the Stockholm3 test and magnetic resonance imaging","volume":"2","author":"Palsdottir","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.urology.2016.08.022","article-title":"Risk stratification by urinary prostate cancer gene 3 testing before magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy among men with no history of biopsy","volume":"99","author":"Fenstermaker","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.jacr.2023.02.010_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1515\/cclm-2019-0693","article-title":"Biomarkers for prostate cancer: prostate-specific antigen and beyond","volume":"58","author":"Duffy","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacr.2023.02.010_bib17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.euf.2017.02.017","article-title":"Prognostic biomarkers used for localised prostate cancer management: a systematic review","volume":"4","author":"Lamy","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.jacr.2023.02.010_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrurol.2015.242","article-title":"Imaging and evaluation of patients with high-risk prostate cancer","volume":"12","author":"Bjurlin","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1148\/radiol.2018180788","article-title":"Diagnostic accuracy of (68)Ga-PSMA-11 PET\/MRI compared with multiparametric MRI in the detection of prostate Cancer","volume":"289","author":"Hicks","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.jacr.2023.02.010_bib20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jncimonographs\/lgs031","article-title":"Overdiagnosis of prostate cancer","volume":"2012","author":"Sandhu","year":"2012","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.jacr.2023.02.010_bib21","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schroder","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacr.2023.02.010_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A\u00a016-yr follow-up of the European Randomized Study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib23","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacr.2023.02.010_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouviere","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacr.2023.02.010_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacr.2023.02.010_bib28","first-page":"CD012663","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacr.2023.02.010_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2012.06.004","article-title":"Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review","volume":"63","author":"Moore","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2019.05.004","volume":"2","author":"Woo","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib31","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2214\/AJR.17.18056","article-title":"Shear-wave elastography for detection of prostate cancer: a systematic review and diagnostic meta-analysis","volume":"209","author":"Woo","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2023.02.010_bib32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00345-015-1714-1","article-title":"Additional elastography-targeted biopsy improves the agreement between biopsy Gleason grade and Gleason grade at radical prostatectomy","volume":"34","author":"Boehm","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.euo.2018.10.001","article-title":"Comparison of the diagnostic accuracy of micro-ultrasound and magnetic resonance imaging\/ultrasound fusion targeted biopsies for the diagnosis of clinically significant prostate cancer","volume":"2","author":"Lughezzani","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib34","first-page":"1166","article-title":"Multiparametric ultrasound for prostate cancer detection and localization: correlation of B-mode, shear wave elastography and contrast enhanced ultrasound with radical prostatectomy specimens","volume":"202","author":"Mannaerts","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib35","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00330-017-5192-2","article-title":"A\u00a0direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness","volume":"28","author":"Baur","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jacr.2023.02.010_bib36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.urology.2019.07.026","article-title":"Prostate contrast enhanced transrectal ultrasound evaluation of the prostate with whole-mount prostatectomy correlation","volume":"133","author":"Trabulsi","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.jacr.2023.02.010_bib37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1470-2045(08)70203-1","article-title":"MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study","volume":"9","author":"Heesakkers","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib38","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2013.07.032","article-title":"Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer","volume":"64","author":"Birkhauser","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2017.01.042","article-title":"Diagnostic performance of Prostate Imaging Reporting and Data System Version 2 for detection of prostate cancer: a systematic review and diagnostic meta-analysis","volume":"72","author":"Woo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib40","first-page":"690","article-title":"Prospective evaluation of the Prostate Imaging Reporting and Data System Version 2 for prostate cancer detection","volume":"196","author":"Mertan","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2214\/AJR.16.17289","article-title":"Accuracy and interobserver agreement for Prostate Imaging Reporting and Data System, Version 2, for the characterization of lesions identified on multiparametric MRI of the prostate","volume":"209","author":"Purysko","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2023.02.010_bib42","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jmri.25948","article-title":"All over the map: an interobserver agreement study of tumor location based on the PI-RADSv2 sector map","volume":"48","author":"Greer","year":"2018","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jacr.2023.02.010_bib43","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.acra.2018.08.013","article-title":"Interobserver agreement and positivity of PI-RADS Version 2 among radiologists with different levels of experience","volume":"26","author":"Mussi","year":"2019","journal-title":"Acad Radiol"},{"key":"10.1016\/j.jacr.2023.02.010_bib44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eururo.2017.02.026","article-title":"What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel","volume":"72","author":"Moldovan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib45","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bju.13619","article-title":"The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting","volume":"119","author":"Hansen","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib46","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/jmri.25040","article-title":"Length of capsular contact for diagnosing extraprostatic extension on prostate MRI: assessment at an optimal threshold","volume":"43","author":"Rosenkrantz","year":"2016","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jacr.2023.02.010_bib47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/0284185116658684","article-title":"Length of capsular contact on prostate MRI as a predictor of extracapsular extension: which is the most optimal sequence?","volume":"58","author":"Woo","year":"2017","journal-title":"Acta Radiol"},{"key":"10.1016\/j.jacr.2023.02.010_bib48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/radiol.2018181278","article-title":"A\u00a0grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI","volume":"290","author":"Mehralivand","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.jacr.2023.02.010_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib50","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2214\/AJR.12.8510","article-title":"Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management","volume":"198","author":"Verma","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2023.02.010_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS Prostate Imaging\u2014Reporting and Data System: 2015, Version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clinimag.2016.01.011","article-title":"Endorectal multiparametric MRI of the prostate: incremental effect of perfusion imaging on biopsy target identification","volume":"40","author":"Romero","year":"2016","journal-title":"Clin Imaging"},{"key":"10.1016\/j.jacr.2023.02.010_bib53","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2214\/AJR.15.14912","article-title":"Assessment of prostate cancer aggressiveness by use of the combination of quantitative DWI and dynamic contrast-enhanced MRI","volume":"206","author":"Hotker","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2023.02.010_bib54","doi-asserted-by":"crossref","first-page":"W226","DOI":"10.2214\/AJR.18.19880","article-title":"Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta-analysis","volume":"211","author":"Woo","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2023.02.010_bib55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrclinonc.2015.70","article-title":"Prostate cancer: MR-TRUS fusion biopsy\u2014defining a new standard","volume":"12","author":"Klein","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2013.10.048","article-title":"A\u00a0prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial","volume":"66","author":"Wysock","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib57","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","article-title":"The FUTURE Trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies","volume":"75","author":"Wegelin","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.eururo.2018.08.007","article-title":"The SmartTarget Biopsy Trial: a prospective, within-person randomised, blinded trial comparing the accuracy of visual-registration and magnetic resonance imaging\/ultrasound image-fusion targeted biopsies for prostate cancer risk stratification","volume":"75","author":"Hamid","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022059","article-title":"Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: a prospective single center, randomized study","volume":"99","author":"Porreca","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacr.2023.02.010_bib60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2015.03.041","article-title":"A\u00a0randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy","volume":"69","author":"Baco","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.eururo.2016.08.041","article-title":"Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy-naive patients with suspected prostate cancer","volume":"72","author":"Porpiglia","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib62","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bju.13624","article-title":"Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance","volume":"119","author":"Pessoa","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib63","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/jmri.25641","article-title":"Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial)","volume":"46","author":"Jambor","year":"2017","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.jacr.2023.02.010_bib64","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s11255-016-1336-6","article-title":"Midline lesions of the prostate: role of MRI\/TRUS fusion biopsy and implications in Gleason risk stratification","volume":"48","author":"Muthigi","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jacr.2023.02.010_bib65","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/MOU.0b013e3283548154","article-title":"Current status of transrectal ultrasound techniques in prostate cancer","volume":"22","author":"Smeenge","year":"2012","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.11152\/mu-1602","article-title":"Visibility of MRI prostate lesions on B-mode transrectal ultrasound","volume":"20","author":"Steinkohl","year":"2018","journal-title":"Med Ultrason"},{"key":"10.1016\/j.jacr.2023.02.010_bib67","first-page":"512","article-title":"Contemporary impact of transrectal ultrasound lesions for prostate cancer detection","volume":"172","author":"Onur","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib68","first-page":"71","article-title":"Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate","volume":"142","author":"Hodge","year":"1989","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib69","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/386207","article-title":"Beyond diagnosis: evolving prostate biopsy in the era of focal therapy","volume":"2011","author":"Dominguez-Escrig","year":"2011","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.jacr.2023.02.010_bib70","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1464-410X.2008.08255.x","article-title":"Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study","volume":"103","author":"Kvale","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib71","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance","volume":"29","author":"Porten","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.urology.2016.11.012","article-title":"Should hypoechoic lesions on transrectal ultrasound be sampled during magnetic resonance imaging-targeted prostate biopsy?","volume":"105","author":"Shakir","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.jacr.2023.02.010_bib73","first-page":"1571","article-title":"Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values","volume":"151","author":"Keetch","year":"1994","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib74","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1464-410X.2012.11607.x","article-title":"Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial","volume":"111","author":"Ploussard","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib75","first-page":"2435","article-title":"Serial biopsy results in prostate cancer screening study","volume":"167","author":"Roehl","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib76","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.canep.2013.08.015","article-title":"When less is more: a simple predictive model for repeated prostate biopsy outcomes","volume":"37","author":"Vencalek","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jacr.2023.02.010_bib77","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2012.10958.x","article-title":"When serial prostate biopsy is recommended: most cancers detected are clinically insignificant","volume":"110","author":"Zaytoun","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib78","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1111\/bju.13850","article-title":"Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer\u2014results from a large contemporaneous cohort","volume":"120","author":"KandaSwamy","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00345-017-2096-3","article-title":"(99m)Tc-HDP bone scintigraphy and (18)F-sodiumfluoride PET\/CT in primary staging of patients with prostate cancer","volume":"36","author":"Wondergem","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib80","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.crad.2017.08.004","article-title":"Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis","volume":"73","author":"Suh","year":"2018","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jacr.2023.02.010_bib81","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41391-018-0113-2","article-title":"Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis","volume":"22","author":"Cantiello","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jacr.2023.02.010_bib82","first-page":"910","article-title":"The Magnetic Resonance Imaging in Active Surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies","volume":"203","author":"Amin","year":"2020","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib83","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2015.10.010","article-title":"Nine-year follow-up for a study of diffusion-weighted magnetic resonance imaging in a prospective prostate cancer active surveillance cohort","volume":"69","author":"Henderson","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib84","first-page":"300","article-title":"Genomic Prostate Score, PI-RADS version 2 and progression in men with prostate cancer on active surveillance","volume":"201","author":"Kornberg","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib85","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/bju.14248","article-title":"Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?","volume":"122","author":"Bryant","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib86","first-page":"84","article-title":"Predicting Gleason group progression for men on prostate cancer active surveillance: role of a negative confirmatory magnetic resonance imaging-ultrasound fusion biopsy","volume":"201","author":"Bloom","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib87","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.urology.2019.08.035","article-title":"Systematic biopsy does not contribute to disease upgrading in patients undergoing targeted biopsy for PI-RADS 5 lesions identified on magnetic resonance imaging in the course of active surveillance for prostate cancer","volume":"134","author":"Arabi","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.jacr.2023.02.010_bib88","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000486041","article-title":"Evaluation of magnetic resonance imaging\/ultrasound-fusion biopsy in patients with low-risk prostate cancer under active surveillance undergoing surveillance biopsy","volume":"100","author":"Borkowetz","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.jacr.2023.02.010_bib89","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2018.06.025","article-title":"Active Surveillance Magnetic Resonance Imaging Study (ASIST): results of a randomized multicenter prospective trial","volume":"75","author":"Klotz","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib90","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.eururo.2016.05.021","article-title":"The role of multiparametric magnetic resonance imaging\/ultrasound fusion biopsy in active surveillance","volume":"71","author":"Ma","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib91","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00345-015-1749-3","article-title":"Can MRI\/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?","volume":"34","author":"Pepe","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib92","first-page":"374","article-title":"The efficacy of multiparametric magnetic resonance imaging and magnetic resonance imaging targeted biopsy in risk classification for patients with prostate cancer on active surveillance","volume":"196","author":"Recabal","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib93","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clinimag.2011.11.028","article-title":"Local staging of prostate cancer: comparative accuracy of T2-weighted endorectal MR imaging and transrectal ultrasound","volume":"36","author":"Jung","year":"2012","journal-title":"Clin Imaging"},{"key":"10.1016\/j.jacr.2023.02.010_bib94","first-page":"727","article-title":"Serial Anatomical prostate ultrasound during prostate cancer active surveillance","volume":"196","author":"Eltemamy","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib95","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","article-title":"Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Zhou","year":"2019","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.jacr.2023.02.010_bib96","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s00330-018-5813-4","article-title":"Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging","volume":"29","author":"Johnston","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jacr.2023.02.010_bib97","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/1754-9485.12885","article-title":"Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: a retrospective review in a private centre","volume":"63","author":"Haran","year":"2019","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib98","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.crad.2019.06.022","article-title":"The role of (18)F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis","volume":"74","author":"Kim","year":"2019","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jacr.2023.02.010_bib99","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/21681805.2015.1005665","volume":"49","author":"Evangelista","year":"2015","journal-title":"Scand J Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib100","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s12094-018-1985-2","article-title":"Diagnostic performance of (18)F-choline PET-CT in prostate cancer","volume":"21","author":"Samper Ots","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib101","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2214\/AJR.17.18567","article-title":"(18)F-fluorocholine PET whole-body MRI in the staging of high-risk prostate cancer","volume":"210","author":"Metser","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2023.02.010_bib102","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00259-017-3875-1","article-title":"Prospective evaluation of (18)F-FACBC PET\/CT and PET\/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial)","volume":"45","author":"Jambor","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jacr.2023.02.010_bib103","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2967\/jnumed.117.198598","article-title":"Combined (18)F-fluciclovine PET\/MRI shows potential for detection and characterization of high-risk prostate cancer","volume":"59","author":"Elschot","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jacr.2023.02.010_bib104","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00259-016-3562-7","article-title":"A\u00a0PET\/MRI study towards finding the optimal [(18)F]fluciclovine PET protocol for detection and characterisation of primary prostate cancer","volume":"44","author":"Elschot","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jacr.2023.02.010_bib105","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1007\/s00330-017-5213-1","article-title":"(18)F-fluciclovine PET\/MRI for preoperative lymph node staging in high-risk prostate cancer patients","volume":"28","author":"Selnaes","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jacr.2023.02.010_bib106","first-page":"734","article-title":"[(18)F]fluciclovine positron emission tomography\/computerized tomography for preoperative staging in patients with intermediate to high risk primary prostate cancer","volume":"204","author":"Alemozaffar","year":"2020","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib107","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12149-019-01343-y","article-title":"(18)F-NaF-PET\/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies","volume":"33","author":"Sheikhbahaei","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.jacr.2023.02.010_bib108","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00345-018-2547-5","article-title":"Impact of sodium (18)F-fluoride PET\/CT, (18)F-fluorocholine PET\/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study","volume":"37","author":"Gauthe","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib109","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2010.31.4252","article-title":"Outcomes of active surveillance for men with intermediate-risk prostate cancer","volume":"29","author":"Cooperberg","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2014.284","article-title":"Risk group and death from prostate cancer: implications for active surveillance in men with favorable intermediate-risk prostate cancer","volume":"1","author":"Raldow","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jacr.2023.02.010_bib111","first-page":"1117","article-title":"Risk of metastasis in men with grade group 2 prostate cancer managed with active surveillance at a tertiary cancer center","volume":"203","author":"Carlsson","year":"2020","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib112","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.urology.2019.02.001","article-title":"Downgrading of grade group after radical prostatectomy: comparison of multiparametric magnetic resonance imaging guided fusion biopsy and standard 12-core biopsy","volume":"127","author":"Beksac","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.jacr.2023.02.010_bib113","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.2214\/AJR.15.15761","article-title":"Journal club: identification of bone metastasis with routine prostate MRI: a study of patients with newly diagnosed prostate cancer","volume":"206","author":"Woo","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2023.02.010_bib114","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.20319","article-title":"The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy","volume":"100","author":"Hricak","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jacr.2023.02.010_bib115","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2214\/AJR.11.6425","article-title":"Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease","volume":"197","author":"Muglia","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jacr.2023.02.010_bib116","first-page":"65","article-title":"Combined whole body and multiparametric prostate magnetic resonance imaging as a 1-step approach to the simultaneous assessment of local recurrence and metastatic disease after radical prostatectomy","volume":"198","author":"Robertson","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib117","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/MNM.0000000000000749","article-title":"Comparison of 68Ga-PSMA PET\/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer","volume":"38","author":"Tulsyan","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.jacr.2023.02.010_bib118","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis","volume":"74","author":"Han","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib119","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacr.2023.02.010_bib120","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clgc.2018.07.009","article-title":"(68)Ga-PSMA PET\/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli?","volume":"16","author":"Lengana","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jacr.2023.02.010_bib121","first-page":"1436","article-title":"Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jacr.2023.02.010_bib122","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.2967\/jnumed.117.207696","article-title":"One-stop-shop whole-body (68)Ga-PSMA-11 PET\/MRI compared with clinical nomograms for preoperative T and N staging of high-risk prostate cancer","volume":"59","author":"Thalgott","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jacr.2023.02.010_bib123","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.119.234187","article-title":"Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard","volume":"61","author":"Kuten","year":"2020","journal-title":"J\u00a0Nucl Med"}],"container-title":["Journal of the American College of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1546144023001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1546144023001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:30:57Z","timestamp":1761546657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1546144023001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":123,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1546144023001813"],"URL":"https:\/\/doi.org\/10.1016\/j.jacr.2023.02.010","relation":{},"ISSN":["1546-1440"],"issn-type":[{"value":"1546-1440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACR Appropriateness Criteria\u00ae Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacr.2023.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Radiology","name":"copyright","label":"Copyright"}]}}